Many of the top cancer drug makers sell their products in a one-sized vial that has enough of the drug in it to treat a person who is 6 feet 6 inches tall and weighs 250 pounds, according to a new study published in BMJ.
For patients who don’t fit that profile, it means that a lot of money is wasted on drugs they don’t use, according to a New York Times story on the study. The annual waste is almost $3 billion.
Why not just save the leftover medicine? Nurses have to discard any excess for safety reasons. Only specialized pharmacies reuse the leftovers, and even then, only within six hours of opening a vial.
From the Times story:
“Drug companies are quietly making billions forcing little old ladies to buy enough medicine to treat football players, and regulators have completely missed it,” said Dr. Peter B. Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering and a co-author of the study. “If we’re ever going to start saving money in health care, this is an obvious place to cut.”
Some of the most recent cancer drugs have an average annual price of $190,000, according to the Times story; Medicare and other insurers can charge co-payments of as much as 20 percent.
The study concludes that insurers paid the drug companies $1.8 billion on the discarded quantities, “and then spent about $1 billion on markups to doctors and hospitals,” according to the Times.
A patient with multiple myeloma receives a weekly dose of 1.8 milligrams of Velcade, but the medicine comes only in 3.5-milligram vials, meaning more than half of the $1,000 drug is wasted every week.
The drug’s manufacturer, Takeda Pharmaceuticals, wrote that it worked with the Food and Drug Administration [FDA] to “ensure that one vial of Velcade would provide an adequate amount of the drug for a patient of almost any size,” but, in Great Britain, the drug is also sold in 1-milligram quantities, according to the Times.
The study expects Takeda to “earn $309 million on supplies of Velcade that are discarded, an amount that represents 30 percent of the drug’s overall sales in the U.S.”
Several doctors remarked to the Times that Europe sells the same drugs in varying and smaller quantities because the regulators are paying attention, whereas the FDA would only object to the large vial sizes if it believed there was a chance of safety issues.
Another drug for metastatic lung cancer and melanoma — Keytruda, developed by Merck — has a sample dosage of 136 milligrams. Previously, Keytruda was only sold in 50-milligram vials, and now it’s only sold in 100-milligram vials, effectively “ensuring waste,” according to the Times.
The 50-milligram vials are still on the market in Europe.
From the Times:
Eighteen of the top 20 cancer medicines are sold in just one or two vial sizes, so on average 10 percent of the volume of cancer drugs purchased by doctors and hospitals is discarded, the researchers say.
This fact-based local reporting drives impact and creates change. Help power that impact.
James Baldwin wrote, “Not everything that is faced can be changed, but nothing can be changed until it is faced.” PublicSource exists to help the Pittsburgh region face its realities and create opportunities for change. When we shine a light on inequity in our region, like the “completely unacceptable” conditions in low-income housing in McKeesport, things change. When we ask questions about policymakers’ decisions, like how Allegheny County is handling COVID-19 safety for its employees, things change. When we push for transparency on issues that affect the public, like in the use of facial recognition software by Pittsburgh police, things change.
It takes a lot of time, skill and resources to produce journalism like this. Our stories are always made available for free so that they can benefit the most people, regardless of ability to pay. But as an independent, nonprofit newsroom, we count on donations from our readers to support this crucial work. Can you make a contribution of any amount (or better yet, set up a recurring monthly gift) to help ensure we can continue to report on what matters and tell stories for a better Pittsburgh?